Although gamma analysis is still a widely accepted quantitative tool to analyze and report patient-specific QA for intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT), the correlation between the 2D percentage gamma passing rate (%GP), and the clinical dosimetric difference for IMRT and VMAT has been questioned. The purpose of this study was to investigate the feasibility of individual volume-based 3D gamma indices for pretreatment VMAT QA.
| MATERIALS AND METHODS

2.A | Study design
As shown in Fig. 1 the flowchart for the overall study design, Oneand two-arc VMAT plans were verified with model-based and measurement-based QA to acquire the percent dose errors (%DE) between planed and QA-reconstructed dose distributions, as well as the global gamma passing rate (%GP) and individual volume-based gamma passing rate (%GP). Statistical correlations between %GP and %DE were investigated using Pearson's correlation coefficient. The sensitivities of individual volume-based %GP and global %GP were then investigated and compared.
2.B | Patients and planning
Thirty-one nasopharyngeal cancer (NPC) patients who underwent two-arc VMAT treatment and 33 prostate cancer patients who underwent one-arc VMAT treatment were enrolled in this study. For one-arc VMAT plan of prostate cancer patients, target delineation was done by one radiation oncologist according to the contouring guidelines of Radiation Therapy Oncology Group (RTOG)
Trial 0126. 16 GTV encompassed the prostate gland, CTV F I G . 1. Flowchart for the whole study design.
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| 29 encompassed GTV plus the proximal bilateral seminal vesicles. PTV was generated by adding a surrounding margin of 7 mm to CTV. A total of 78 Gy dose was prescribed to PTV at 39 fractions. OARs were outlined according to the Male RTOG Normal Pelvis Atlas.
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For one-arc VMAT optimization, at least 95% of PTV must be covered by 95% of the prescription dose. OAR constraints included rectum, bladder, peritoneal cavity or bowel, femoral heads, and unspecified tissue. A start angle of 181°and a stop angle of 180°w
ere applied for one-arc plans using clockwise (CW) rotation direction. A leaf motion of 0.46 cm/deg and a final arc space degree of 4
were employed for both one-arc and two-arc VMAT.
2.C | Model-based QA and measurement-based QA
In this study, model-based and measurement-based QA were conducted with COMPASS system (version 1.2, IBA Dosimetry, Schwarzenbruck, Germany), 18 which includes an two-dimensional ion chamber (IC) array (MatriXX, IBA Dosimetry) and dose reconstruction software based on a beam model describing the characteristics of the accelerator (e.g., energy spectrum, lateral beam quality variations) and a collapsed-cone convolution/superposition (CCC/S) algorithm.
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A strict commissioning of the whole system, including the validation of accuracy for 2D-IC array measurement, beam modeling, and dose reconstruction, was performed in advance according to the same standards as the clinic used TPS. A 3D dose deposition on the patients' CT dataset was reconstructed without measurement using CCC/S algorithm based on the commissioned fluence model and the dose engine to provide an independent dose verification for TPS calculation.
A measurement-based QA was conducted by using MatriXX IC array with 5 cm RW3 (water-equivalent phantom) (PTW, Germany) 
2.E | Correlation and sensitivity analysis
Statistical correlation between 3D %GP of individual volume and % DE, as well as correlation between global %GP and %DE were investigated using Pearson's correlation coefficient (r) with SPSS 17.0 (spss Inc., Chicago, IL, USA). %DE was assumed to be correlated with a determined %GP when P < 0.05, which was obtained from r. In order to compare the sensitivities of 3D %GP of individual volume and global %GP, the number of "false negative" (FN) cases (cases with high QA passing rates but with large errors in DVH dose metrics) and "true positive" (TP) cases (cases with low QA passing rates and with large errors in DVH dose metrics) were calculated. In particular, we considered all those structures "FN" that had DVH metrics errors > 3% among those patients with %GP > 95%. We considered all the cases "TP" that had DVH metrics errors > 3% and %GP < 95%. From the FN and TP rates, receiver operating characteristic (ROC) curves were generated to investigate the ability of individual volume %GP and global %GP to identify accurately the plan with dose errors > 3%. 6 3 | RESULTS Table 1 shows the average %DE on different DVH metrics between TPS and model-based, measurement-based dose reconstruction from COMPASS for NPC and prostate cancer patients, respectively. Most of %DE of the DVH metrics were within 3%. However, higher dose differences were observed on percentage volume of certain isodose line, such as V95 of GTV for NPC patients, V95 of PTV, V60, V70
of bladder and rectum, and V50 of rectum for prostate cancer patients. D1 of lens, which has a small volume, was also presented with a relatively higher dose difference.
The %GPs of individual volumes and global gamma of NPC and prostate cancer patients with different criteria were shown in Table 2 for both model-based and measurement-based QA analysis.
%GP for individual volumes of PTV (cPTV) and GTV (cGTV) with 2%/2 mm criteria were less than 90% for both NPC and prostate the TPS-calculated dose versus measured dose. 21 Suggestions even had been made to switch from measurement-based QA to modelbased QA to improve the time efficiency since research had shown that no dose delivery error occurred in 99.5% of the treatment plans. 22 In this study, the VMAT dose calculation performed by Pinnacle TPS was verified with the COMPASS system using an inbuilt beam model as a model-based QA process. The %DE of modelbased QA for most of DVH metrics of VMAT plans were within 3%, except for some metrics with sharp dose gradient (such as V95 and V70), and metrics with small volumes (lens). This is a bit different from reported IMRT QA with a second TPS, in which a very high agreement ratio (0.999) between initial and second TPS calculation were presented. 23 However, only one point dose difference was reported in that study.
Although model-based QA is time efficient and clinically feasible, 21 IMRT and VMAT treatments also involve complex linac Similar to the reported lacking of correlation between %GP and clinical relevant metrics in previous IMRT and VMAT measurementbased QA, 6, 24 in this study, the correlations between global %GP and DVH metrics dose differences were very weak for two-arc VMAT NPC (2 out of 15). The correlation between global %GP and DVH metrics dose differences for one-arc VMAT prostate was better with 2%/2 mm criteria, but it was still very weak for clinical generally accepted gamma criteria 3%/3 mm (12 out of 23), and it was very weak for 4%/4 mm criteria (1 out of 23).
%GP
Due to this lack of correlation between global %GP and %DE, DVH metrics-based QA comparing directly the TPS calculated and measured 3D dose distribution for IMRT and VMAT has been suggested. 6, 25 The accuracy and feasibility of COMPASS 3D verification system for IMRT and VMAT plans have been investigated by many authors. 18, 26, 27 A bit larger %DE between two algorithms on some 
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